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Background: Activated leukocytes may contribute to the development and progression of heart failure 
(HF).  We investigated the predictive value of circulating levels of stable and readily detectable markers 
reflecting both monocyte/macrophage and T-cell activity, on clinical outcomes in heart failure (HF) 
patients with reduced ejection fraction (HFrEF). Methods: The association between baseline plasma 
levels of soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF), granulysin, soluble 
interleukin-2 receptor (sIL-2R), and activated leukocyte cell adhesion molecule (ALCAM) and the primary 
endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using 
multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate 
anemia, enrolled in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial. Modifying 
effects and interaction with darbepoetin alfa treatment were also assessed. Results: All leukocyte 
markers, except granulysin, were associated with the primary outcome and all-cause death in univariate 
analysis (all p<0.01) and remained significantly associated in multivariable analysis adjusting for 
conventional clinical variables (e.g. age, gender, BMI, NYHA class, creatinine, LVEF, etiology) and CRP.  
However, after final adjustment for TnT and NT-proBNP no associations were found with outcomes. No 
interaction with darbepoetin alpha treatment was observed for any marker. 
Conclusions: Leukocyte activation markers sCD163, MIF, sIL-2R, and ALCAM were associated with 
adverse outcome in patients with HFrEF, but add little as prognostic markers on top of established 
biochemical risk markers. 
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT00358215 










Heart failure (HF) is a progressive disorder with an element of immune activation and a persistent low 
grade inflammation [1-4]. Activated monocytes/macrophages and T cells release a variety of inflammatory 
cytokines that have direct effects on cardiac cells, promoting hypertrophy, fibrosis, and apoptosis [5,6,3]. 
Cytokine secretion from monocytes/macrophages, T cells as well as other leukocyte subpopulations and 
myocardial cells initiate further leukocyte mobilization and recruitment to the myocardium, which creates a 
vicious circle, further promoting the development of HF [3].  
Multiple circulating cytokines are increased in HF patients systemically but they frequently 
circulate at relatively low levels which limits their analytical performance and discriminatory properties 
beyond established clinical markers of HF [7]. Some markers reflecting general or more specific leukocyte 
activation, circulate at readily detectable levels, but have been scarcely evaluated in large HF 
populations, with a few exceptions. Circulating myeloperoxidase, an enzyme primarily secreted by 
activated granulocytes, gave no prognostic information in adjusted analysis in 1513 HF patients with 
reduced ejection fraction (HFrEF) [8]. In contrast, galectin 3, which may partly reflect macrophage 
activation, has received wide attention in predicting adverse outcomes and response to therapy in HF 
patients potentially reflecting its ability to reflect both extracellular matrix (ECM) and inflammation [9]. 
Anemia is frequently observed in HF and associated with poor prognosis [10-12]. Based on the 
established role of persistent leukocyte activation in anemia [13] and its emerging role in the progression 
of HF, we hypothesized that plasma levels of stable and readily detectable markers of leukocyte 
activation, reflecting both monocyte/macrophage (soluble [s] CD163 [14], macrophage migration inhibitory 
factor [MIF] [15]) and/or T-cell (soluble interleukin 2 receptor [sIL-2R] [16], activated leukocyte cell 
adhesion molecule [ALCAM] [17], granulysin [18]) activity could represent clinically relevant inflammatory 
biomarkers in HF patients. We therefore evaluated if they could predict clinical outcomes in 1588 anemic 
patients with HFrEF in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial [19]. In 
general, the intervention with darbepoetin alfa did not show any effects on the primary end-point, but a 
secondary aim in this study was to evaluate if these markers could identify subgroups of patients who 





Materials and Methods 
Patients and Study Procedures 
The study design and baseline characteristics of the RED-HF trial have been reported in detail previously 
[20,21]. Patients were eligible for the study if they had the New York Heart Association (NYHA) functional 
class II-IV; systolic HF with left ventricular ejection fraction (LVEF) ≤ 40%; a hemoglobin level of 9.0 to 
12.0 g per deciliter and were receiving guideline-recommended HF therapy. Major exclusion criteria were 
a transferrin saturation of less than 15%, evidence of bleeding or other correctable causes of anemia, a 
serum creatinine level of more than 3 mg per deciliter (265 μmol per liter), and a blood pressure of more 
than 160/100 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either darbepoetin alfa or 
placebo. The study drug was administered subcutaneously, with doses adjusted according to hemoglobin 
level, which was measured in a blinded fashion. Patients in the darbepoetin alfa group received a starting 
dose of 0.75 μg per kilogram of body weight once every 2 weeks until a hemoglobin level of 13.0 g per 
deciliter was reached on two consecutive visits. Thereafter, patients received monthly injections, 
according to an algorithm [20] that was designed to maintain a hemoglobin level of 13.0 g per deciliter 
(but not exceeding 14.5 g per deciliter). Patients in the placebo group received dose adjustments to mimic 
those in the darbepoetin alfa group. The trial complied with the Declaration of Helsinki and was approved 
by the Ethics Committees of the participating hospitals. All patients provided a written informed consent. 
 
Study outcomes and definitions 
The primary predefined outcome was a composite of death from any cause or first hospitalization for 
worsening of HF. The prespecified adjudicated secondary outcomes were 1) composite of death from 
cardiovascular (CV) causes or first hospitalization for worsening of HF, 2) death from any cause, 3) CV 
death. Details on the definition and adjudication of all outcomes have been described previously [19].  
 
Blood sampling and biochemical analysis 
All blood samples were non-fasting and all reported measurements, except for markers of leukocyte 
activation, were performed at a central laboratory, including N-terminal pro-brain natriuretic peptide (NT-
proBNP) and high sensitivity assays for C-reactive protein (hsCRP) and troponin T (hsTnT) (Medical 
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Research Laboratories, Zaventem, Belgium). Blood samples for the measurement of the cytokines were 
collected in pyrogen-free EDTA tubes; centrifuged and isolated plasma was stored at –80°C until 
analyses. All samples were thawed an equal number of times (<3 times) and were on the bench <2 hours 
when preparing analysis. Circulating sCD163, MIF, granulysin, sIL-2R, and ALCAM were analyzed by 
enzyme immunoassays from R&D Systems (Minneapolis, MN, USA) with intra- and inter-assay 
coefficients of variation < 10%. The effect of postprandial and diurnal variation, time-delay on bench and 
in fridge and freeze-thaw cycles are presented in Supplemental Table 1 while marker levels according to 
inclusion year and time of day are presented in Supplemental Figure 1. 
 
Statistical analysis 
Trends across tertiles of the leukocyte markers were tested using Kruskal-Wallis H test, one-way ANOVA 
or chi-square depending on distribution and variable type (i.e. categorical or continuous). For comparing 
treatment effects on the markers, the Mann-Whitney U test was used on change values while Wilcoxon 
matched pairs test was used to assess longitudinal changes within groups. Stepwise linear regression 
was used to identify the most important predictors of the leukocyte markers. Kaplan-Meier curves were 
constructed to visualize and evaluate (log rank test) differences in survival. A restricted cubic spline 
analysis with three knots was undertaken on the primary outcome to assess linearity of risk. Survival 
analyses were performed using the Cox proportional hazard regression models to estimate hazard ratios 
(HRs) and 95% confidence intervals (CIs) for the leukocyte activation markers as a log-transformed 
continuous variables at baseline, which included mainly clinical variables at step one (age, gender, NYHA 
class, hospitalization for HF within 6 months, log serum creatinine, LVEF, etiology, body mass index 
(BMI), left bundle-branch block, history of atrial fibrillation or flutter, systolic blood pressure). At step two, 
log-transformed serum concentrations of hsCRP were included and finally, NT-proBNP and hsTnT were 
included at step three. A two-sided p-value <0.05 was considered to be significant. All statistical analyses 







Stability of T cell and monocyte/macrophage activation markers  
As shown in Supplemental Figure 1, there was no association between time (i.e. year) or time of isolation 
during the day and marker level, except sCD163 was higher at midday. The distribution of marker level was 
similar at all time-points assessed. As shown in Supplemental Figure 1, no effect of fasting on biomarker 
levels was observed although there did appear to be some fluctuation over the day with increased levels of 
sCD163, Granulysin, ALCAM at noon (non-fasting). As also shown in Supplemental Table 1, time delay 
experiments, achieved by leaving samples on the bench or in the fridge for up to 24 hours, revealed no 
large major loss over time, although sCD163 and ALCAM tended to decline after 4 hours on bench and in 
the fridge and all markers was lower after 24 hours in the fridge. Finally, the effect of freeze thaw cycles 
had minor effects on marker levels.    
 
Plasma levels of T cell and monocyte/macrophage activation markers in the RED-HF Cohort 
Of the 2,278 patients enrolled in the RED-HF study, samples for measurement of the T cell and 
monocyte/macrophage activation markers were available for 1,582 (69%). The median plasma level of 
sCD163 at baseline in the overall population was 0.64 µg/mL (IQR 0.41 to 1.00 µg/mL); MIF 1.7 (1.1 to 
2.5 ng/mL); granulysin 1.5 ng/mL (1.1 to 2.0 ng/mL); sIL-2R 277 pg/mL (189 to 409 pg/mL); ALCAM (175 
ng/mL) 136 to 661 ng/mL. Clinical characteristics of the study population are given in Table 1 (Table 1). 
Clinical characteristics according to the tertiles of leukocyte markers are shown in Supplementary Table 
2. Several demographic and clinical variables were associated with most of these markers, such as race, 
kidney function, hsCRP, hsTnT and NT-proBNP. None or few associations were found with NYHA class, 
LVEF and BMI. Of relevance to this patient population that also had anemia, high sIL-2R and ALCAM 
levels were associated with low hemoglobin levels, and high sIL-2R and sCD163 also correlated with low 
transferrin saturation. 
Supplemental Table 3 shows predictors of levels of the monocyte/macrophage/T cell markers 
identified by stepwise linear regression. The four strongest significant predictors of the markers were, for 
sCD163: race, hsTnT, platelet count and hsCRP; for MIF: heart rate, hsTnT and age; for granulysin: 
eGFR, race, gender and previous MI; for sIL-2R: creatinine, NT-proBNP, hsCRP and race; for ALCAM: 
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creatinine, race, hsTnT and sex.  
 
Association between baseline levels of T cell and monocyte/macrophage activation markers and outcome 
in RED-HF trial  
During a mean follow-up of 2.3 years (range 0.0-6.0 years), 798 patients reached the primary end point, 
716 patients reached the composite of death from cardiovascular (CV) causes or first hospitalization for 
worsening of HF, while 649 patients died and of these, 543 due to CV causes. Kaplan-Meier estimates for 
the primary endpoint according to baseline tertiles of the measured leukocyte markers are presented in 
Figure 1. A moderate association with the primary outcome was observed for all markers, with a more 
defined tertile effect for sIL-2R, than for the other proteins. Also, for granulysin, the lowest outcome was 
observed in tertile 2, suggesting a non-linear U-shaped association with outcome, which was confirmed 
by a restricted cubic spline analysis (Supplementary Figure 2). For the other markers, the cubic spline 
analysis against the primary endpoint revealed a linear increase in the first and second tertile, followed by 
flattening of the curve around tertile 3 (Supplementary Figure 2).   
When investigating the associations between log-transformed values of the inflammatory markers 
and outcome, univariate Cox proportional hazard models including the markers separately showed that all 
of them except granulysin were significantly associated with the primary outcome (Figure 2A), with the 
strongest association for sIL-2R. These markers remained significantly associated with the primary 
outcome and all-cause death in multivariable analysis, adjusting for a wide range of conventional clinical 
variables (i.e. age, gender, BMI, NYHA class, HF hospitalization last 6 months, creatinine, LVEF, etiology, 
left bundle-branch block, history of atrial fibrillation or flutter, systolic blood pressure (BP) and study drug) 
(Step 1). sCD163, MIF, and sIL-2R were only marginally affected and still significantly associated with 
both outcomes after further adjustment for hsCRP (Step 2). ALCAM remained significantly associated 
with all-cause death, but not with the primary outcome. However, associations with outcomes were 
markedly attenuated after the last adjustment for hsTnT and NT-proBNP showing no significant 
associations with outcome (Step 3). Similar, but less prominent trends were seen for the secondary 
endpoints of CV death or first hospitalization for worsening of HF and CV death, with the strongest 
association for MIF and sIL-2R (Table 3). 
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 As shown in Supplemental Table 2, there was a tendency for higher frequency of patients with high 
levels of leukocyte markers in patients with diabetes, significant for sCD163 and sIL-2R, while granulysin 
was lower. Based on the high frequency of diabetes in RED-HF we evaluated risk of adverse outcome in 
patients with (HbA1c mean±SD: 7.39±1.61 %) and without (5.75±0.64 %) diabetes separately, restricting 
analysis to fully adjusted models. As shown in Supplementary Table 4, only sCD163 displayed a trend of 
increased risk according to diabetes status with a higher risk in non-diabetic patients which was significant 
for all-cause death. 
Effect of darbepoetin alfa on markers of T cell and monocyte/macrophage activation 
Table 3 shows levels of the leukocyte markers at baseline and after 6 months treatment with darbepoetin 
alfa or placebo. There were no significant differences in the levels of the measured inflammatory markers 
between placebo and darbepoetin alfa groups at baseline. MIF increased after treatment with darbepoetin 
alfa giving significantly higher levels at 6 moths and a significant difference in change between the treatment 
groups, while sIL-2R decreased. Leukocyte markers did not change in placebo group. No association 
between change in any of the markers (i.e. decrease: <-15%, no change: 15%-15%, increase: >15% or 
evaluated as tertile change) and any outcome was observed (p-values between 0.08 – 0.92). No interaction 
between baseline levels or change of any of the markers and darbepoetin alpha on any outcome was 
observed (p-values for interaction 0.07-0.99). 
 
Discussion 
In 1582 patients with HFrEF and mild to moderate anemia, circulating markers reflecting 
monocyte/macrophage and T cell activation were associated with adverse outcomes following adjustment 
for a wide range conventional risk variables, including hsCRP, supporting a role for leukocyte activation in 
the progression of HF. However, the associations were markedly attenuated after further adjustment for 
hsTnT and NT-proBNP, limiting their clinical usefulness as biomarkers in HF. Darbepoetin alpha 
treatment increased MIF levels, but no interaction with baseline levels of any of the leukocyte markers 
and treatment on outcomes was observed. 
The systemic immune activation in HF as reflected by high levels of various inflammatory 
cytokines in plasma or serum could at least partly reflect systemic activation of various leukocyte 
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subpopulations such as T cell and monocyte/macrophages. This activation of leukocyte subpopulations 
could again be mirrored by soluble markers such as those investigated in this study. Our evaluation of 
these markers with regard to long term stability (i.e. association between marker level and inclusion year) 
and bench stability, suggest they are robust markers with adequate pre-analytical characteristics. In 
addition to systemic inflammation, however, these markers could also reflect myocardial inflammation. 
Indeed, linear regression identified hsTnT as a strong predictor for most leukocyte markers. Since 
leukocyte activation and migration from the circulation to areas of myocardial inflammation may contribute 
to the tissue injury in chronic HF [3,6,5], circulating levels of these markers could therefore also reflect 
ongoing myocardial inflammation. Recently, Ptaszynska-Kopczynska found higher serum levels of 
sCD163 in 79 patients with HFrEF [22]. As for sIL-2R, we and others have reported increased circulating 
sIL-2R levels in HF [23,24], associated with a more aggressive clinical course [24]. Apart from these 
smaller studies, we could find no reports on our selected markers as predictors of adverse outcomes in 
large HF populations. However, we have previously shown in the present RED-HF population that 
although CRP is associated with poor prognosis following adjustment for conventional risk factors (i.e. 
step 1 in our adjustment strategy), it does not add information on top of NT-proBNP and TnT. Thus, our 
finding that high plasma levels of sCD163, MIF, sIL-2R and ALCAM were associated with the primary 
endpoint and all-cause mortality after adjustment for conventional risk factors and only modestly affected 
by adjustment for hsCRP supports that T cell and monocyte/macrophage activation markers may reflect 
ongoing myocardial inflammation and could be of importance in the progression of HF. However, the 
strong association between all leukocyte markers and NT-proBNP and hsTnT in RED-HF could contribute 
to the strong attenuation of risk in multivariable analysis when these established risk markers were 
included, limiting the clinical usefulness of soluble markers of T cell and monocyte/macrophage 
activation.  
Patients with HF and diabetes have particularly poor outcome and increased inflammatory burden 
[12,25] as also observed for sCD163 and sIL-2R in diabetes patients in the present population. However, 
we found no evidence of increased risk in diabetic patients. In contrast, in patients without diabetes, high 
sCD163 levels were associated with enhanced risk of all-cause mortality, also in adjusted analysis. 
Consequently, enhanced immune activation, as reflected by the leukocyte markers assessed in the 
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present study, does not seem to confer additional risk of adverse outcomes in the presence of diabetes, 
at least in HF patients with anemia. Similarly, sIL-2R and ALCAM were also associated with ischemic 
etiology and sIL-2R with stroke and MI the last 6 months, which also carries an ischemic component. 
However, all markers were more strongly correlated with both NT-proBNP and TnT levels suggesting that 
myocardial inflammation per se is more impactful than that of ischemic etiology in patients with anemia 
and advanced chronic HF. Possibly, the burden of anemia masks relevant associations and our results 
cannot be generalized to HF patients without anemia or other inflammatory markers.  
The cause of anemia in patients with HF may be related to an absolute or relative deficiency of, 
or resistance to, erythropoietin (EPO), to which inflammation may contribute through bone marrow 
suppression [26,27]. EPO administration has been shown to both reduce and augment inflammatory 
responses in circulating leukocytes [28-30]. Interestingly, darbepoetin alpha treatment was associated 
with an increase in MIF, which helps to sustain macrophage activation and is an important mediator of 
anemic complications and bone marrow suppression during malaria infection [31,32], and could therefore 
also contribute to resistance to EPO. Furthermore, in patients with chronic kidney disease, non-
responders to EPO treatment are characterized by enhanced activation of both monocytes [33] and T 
cells [34]. Thus, although the RED-HF trial failed to detect a benefit of an erythropoiesis stimulating agent 
on clinical outcomes, leukocyte activation markers could be potentially identify patients that could have 
advantage of EPO treatment. However, no interaction between darbepoetin alpha treatment and baseline 
or change in levels during follow-up of any of the leukocyte markers on outcome was observed.  
The strengths of the present investigation include the large number of patients studied with a high 
event rate and adjustment for multiple relevant confounders. On the other hand, a randomized trial may 
not necessarily reflect the “real-world” HF population and the use of composite endpoints has an inborn 
limitation. In addition, the trial populations had mild to moderate anemia, a high frequency of renal 
dysfunction and all markers were strongly influenced by race. The baseline association between 
circulating markers and outcome may therefore not apply to all HF patients. Finally, our interpretations are 
limited to our choice of markers, which represent less studied markers in the context of HF. Other 
markers of monocyte/macrophage activation such as neopterin and soluble CD14 have been associated 
with HF progression following ACS [35] and all-cause mortality in elderly [36] are possible candidates. 
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In conclusion, although our data support activation of monocytes/macrophages and T cells in the 
progression of HF, the lack of independence from hsTnT and NT-proBNP limits their clinical usefulness 
as prognostic markers in this population. However, our findings do not rule out that other leukocyte 
activation markers may prove useful.  
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Figure 1. Association between baseline levels of leukocyte markers and all-cause mortality in the RED-
HF cohort. Kaplan-Meier curves showing the cumulative incidence of all-cause mortality (n=1541) during 
the whole study (mean follow-up 2.3 years, range 0.0-6.0 years), according to tertiles at enrollment.   
 
Figure 2. Association between baseline levels of leukocyte markers and (A) primary outcome or (B) all-
cause death in the RED-HF study. Hazard ratios (HRs) and 95% confidence interval (CI) per SD change 
with P-values are shown for univariate (UNI) analysis, when adjusted for clinical and biochemical 






















Table 1. Patient demographics 
Characteristic Sub-study 
 (n=1588) 
Age yrs, mean (SD) 70 (12) 
Female sex, n (%) 685 (43) 
Race (white/black), n (%) 1052/156 (66/10) 
BMI kg/m2, mean (SD) 27.1 (5.7) 
NYHA (III or IV) n (%) 1057 (66) 
Systolic BP, mean (SD) 120 (18) 
Heart rate b.p.m., mean (SD) 72 (11) 
Ischemic HF, n (%) 1137 (72) 
Duration HF yrs, mean (SD) 5.4 (5.4) 
LVEF %, mean (SD) 30.3 (6.8) 
Medical history  
Hypertension, n (%) 1176 (74) 
Diabetes, n (%) 710 (45) 
Atrial fibrillation or flutter, n (%) 502 (32) 
MI last 6 mo., n (%) 580 (37) 
Medication  
ACE or ARB, n (%) 1428 (90) 
Beta-blocker, n (%) 1351 (85) 
Diuretic, n (%) 1452 (91) 
Biochemistry  
Creatinine mg/dL, mean (SD) 1.5±0.6 
eGFR mL/min/1.73m2, mean (SD) 50±22 
HbA1c %, mean (SD) 6.48±1.43 
Hemoglobin g/dL, mean (SD) 11.0±0.7 
Transferrin saturation %, mean (SD) 27.9±10.9 
Platelets 109/L, mean (SD) 232±79 
WBC 109/L, mean (SD) 6.7±2.2 
hsCRP mg/L, median (IQR) 2.7 (1.1,6.8) 
NT-proBNP pg/mL, median (IQR) 1823 (653,4244) 
hsTnT ng/ml, median (IQR) 25.6 (15.0,42.8) 
Patient characteristics are given as mean ± SD for continuous variables and % of cases for categorical 
variables. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass 
index; BP, blood pressure; MI, myocardial infarction; eGFR, estimated glomerular filtration rate;  hsCRP, 





Table 2. Association between baseline levels of leukocyte markers (continuous) and the secondary 
composite outcome cardiovascular death in the RED-HF study. Hazard ratios (HRs) and 95% confidence 
interval (CI) per log change with P-values are shown for univariate (UNI) analysis, when adjusted for 
clinical and biochemical variables (S1), further adjusted for hsCRP (S2) and lastly for hsTnT and NT-
proBNP (S3). 
  Secondary Composite Cardiovascular Death 
  HR  (95% CI) P-value HR  (95% CI) P-value 
sCD163 Uni 1.18 (1.07—1.30) 0.006 1.17 (1.05—1.31) 0.006 
 S1 1.12 (1.01—1.23) 0.028 1.12 (1.01—1.26) 0.040 
 S2 1.09 (0.98—1.20) 0.10 1.09 (0.98—1.23) 0.13 
 S3 1.02 (0.93—1.12) 0.69 1.03 (0.92—1.16) 0.57 
    
MIF Uni 1.14 (1.06—1.23) 0.001 1.16 (1.07—1.27) 0.014 
 S1 1.11 (1.02—1.20) 0.012 1.15 (1.05—1.26) 0.003 
 S2 1.08 (0.99—1.17) 0.051 1.12 (1.02—1.23) 0.015 
 S3 1.03 (0.94—1.12) 0.54 1.06 (0.96—1.17) 0.23 
    
Granulysin Uni 1.01 (0.92—1.12) 0.093 1.02 (0.91—1.14) 0.50 
 S1 0.92 (0.84—1.01) 0.086 0.93 (0.83—1.04) 0.19 
 S2 0.91 (0.83—1.00) 0.061 0.92 (0.82—1.03) 0.13 
 S3 0.91 (0.83—1.00) 0.053 0.92 (0.82—1.02) 0.11 
    
sIL-2R Uni 1.34 (1.23—1.45) <0.001 1.29 (1.17—1.42) <0.001 
 S1 1.14 (1.04—1.24) 0.005 1.09 (0.98—1.20) 0.12 
 S2 1.11 (1.01—1.21) 0.027 1.05 (0.95—1.16) 0.35 
 S3 1.00 (0.91—1.09) 0.98 0.96 (0.86—1.06) 0.41 
    
ALCAM Uni 1.17 (1.05—1.29) 0.033 1.16 (1.03—1.30) 0.059 
 S1 1.07 (0.97—1.19) 0.19 1.08 (0.96—1.22) 0.22 
 S2 1.06 (0.96—1.18) 0.27 1.07 (0.97—1.21) 0.30 
 S3 0.99 (0.89—1.10) 0.81 1.00 (0.88—1.12) 0.95 
ALCAM, activated leukocyte cell adhesion molecule; MIF, macrophage migration inhibitory 










Table 3. Serum levels of leukocyte markers during placebo and darbepoetin treatment in the RED-HF trial. 
Leukocyte 
marker 
   Placebo Darbepoetin P value  Levels Change Levels Change 
sCD163 
(μg/mL) 
BL 0.78 (0.40, 0.99) 0.01  
(-0.18, 0,22) 
0.80 (0.42, 1.00) -0.10  
(-0.20, 0.23) 0.358 3 mo. 0.79 (0.44, 0.96) 0.80 (0.44, 0.98) 
       
MIF 
(ng/mL) 
BL 2.59 (1.13, 2.50) 0.01  
(-0.65, 0.61) 
2.51 (1.13, 2.45) 0.14  
(-0.41, 0.81) 0.006 3 mo. 2.67 (1.15, 2.35) 2.86 (1.18, 2.78)* 
       
GNLY 
(ng/mL) 
BL 1.6 (1.0, 2.0) 0.0  
(-0.2, 0.2) 
1.6 (1.1, 1.9) 0.0  
(-0.2, 0.2) 0.094 3 mo. 1.6 (1.1, 2.0) 1.6 (1.1, 2.0) 
       
sIL2R 
(ng/mL) 
BL 347 (188, 409) 2  
(-51, 47) 
355 (191, 409) -7  
(-50, 42) 0.199 3 mo. 358 (180, 402) 335 (172, 396)* 
       
ALCAM 
(ng/mL) 
BL 181 (134, 218) 0  
(-25, 23) 
186 (138, 222) -3  
(-27.5, 23) 0.146 3 mo. 181 (135, 216) 182 (134, 216) 
       
hsCRP 
(mg/L) 
BL 2.5 (1.0, 6.6) 0.1  
(-1.4, 2.2) 
2.9 (1.1, 7.1) 0.1  
(-1.6, 2.0) 0.115 6 mo. 2.6 (1.0, 7.0) 2.9 (1.3, 7.1) 
       
NT-proBNP 
(pg/mL) 
BL 1799 (692, 4214) 6.0  
(-536, 534) 
1837 (586, 4262) -36  
(-659, 277) 0.943 6 mo. 1706 (633, 3797) 1568 (462, 3774)* 
       
hsTnT 
(ng/mL) 
BL 25.1 (14.8, 42.5) 0.4  
(-4.4, 4.8) 
26.4 (15.2, 42.8) -0.1  
(-3.7, 4.1) 0.351 6 mo. 24.6 (14.7, 38.9) 24.9 (14.4, 40.4) 
Data are given as median and 25th-75th percentiles. *p<0.05 vs. baseline levels. ALCAM, activated 
leukocyte cell adhesion molecule; hsCRP, high-sensitivity C-reactive protein; hsTnT, high-sensitive 
troponin T; MIF, macrophage migration inhibitory factor; sCD163, soluble cluster of differentiation 163; 
sIL2R, soluble IL-2 receptor; NT-proBNP, N-terminal pro-brain natriuretic peptide 
 
 
 
 
 
 
 
 
